{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T19:15:48Z","timestamp":1790104548024,"version":"4.0.1"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T00:00:00Z","timestamp":1631059200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Breast Cancer Res Treat"],"published-print":{"date-parts":[[2021,11]]},"DOI":"10.1007\/s10549-021-06368-4","type":"journal-article","created":{"date-parts":[[2021,9,8]],"date-time":"2021-09-08T17:02:48Z","timestamp":1631120568000},"page":"183-188","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Patient preferences and adherence to adjuvant GnRH analogs among premenopausal women with hormone receptor positive breast cancer"],"prefix":"10.1007","volume":"190","author":[{"given":"Jasmine S.","family":"Sukumar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dionisia","family":"Quiroga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahmoud","family":"Kassem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Grimm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Namrata Vilas","family":"Shinde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leslie","family":"Appiah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilly","family":"Palettas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret E.","family":"Gatti-Mays","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashley","family":"Pariser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathew","family":"Cherian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel G.","family":"Stover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Van Deusen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Wesolowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Lustberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhuvaneswari","family":"Ramaswamy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2688-0486","authenticated-orcid":false,"given":"Sagar","family":"Sardesai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,9,8]]},"reference":[{"issue":"2","key":"6368_CR1","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1056\/NEJMoa1803164","volume":"379","author":"PA Francis","year":"2018","unstructured":"Francis PA, Pagani O, Fleming GF, Walley BA, Colleoni M, L\u00e1ng I, G\u00f3mez HL, Tondini C, Ciruelos E, Burstein HJ et al (2018) Tailoring adjuvant endocrine therapy for premenopausal breast cancer. N Engl J Med 379(2):122\u2013137","journal-title":"N Engl J Med"},{"key":"6368_CR2","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41598-016-0013-4","volume":"6","author":"L Qiu","year":"2016","unstructured":"Qiu L, Fu FM, Huang M, Lin YX, Chen YZ, Chen MY, Wang C (2016) Evaluating the survival benefit following ovarian function suppression in premenopausal patients with hormone receptor positive early breast cancer. Sci Rep 6:11","journal-title":"Sci Rep"},{"issue":"1","key":"6368_CR3","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1097\/CCO.0000000000000491","volume":"31","author":"M Lambertini","year":"2019","unstructured":"Lambertini M, Viglietti G, de Azambuja E (2019) Impact of ovarian function suppression in premenopausal women with estrogen receptor-positive early breast cancer. Curr Opin Oncol 31(1):43\u201351","journal-title":"Curr Opin Oncol"},{"issue":"5","key":"6368_CR4","doi-asserted-by":"publisher","first-page":"e654","DOI":"10.1016\/j.clbc.2019.06.003","volume":"19","author":"AR Ferreira","year":"2019","unstructured":"Ferreira AR, Ribeiro J, Miranda A, Mayer A, Passos-Coelho JL, Brito M, Fernandes J, Gouveia J, Costa L, Vaz-Luis I (2019) effectiveness of adjuvant ovarian function suppression in premenopausal women with early breast cancer: a multicenter cohort study. Clin Breast Cancer 19(5):e654\u2013e667","journal-title":"Clin Breast Cancer"},{"issue":"5","key":"6368_CR5","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1056\/NEJMoa1412379","volume":"372","author":"PA Francis","year":"2015","unstructured":"Francis PA, Regan MM, Fleming GF, L\u00e1ng I, Ciruelos E, Bellet M, Bonnefoi HR, Climent MA, Da Prada GA, Burstein HJ et al (2015) Adjuvant ovarian suppression in premenopausal breast cancer. N Engl J Med 372(5):436\u2013446","journal-title":"N Engl J Med"},{"issue":"1","key":"6368_CR6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s11864-017-0442-8","volume":"18","author":"M Lambertini","year":"2017","unstructured":"Lambertini M, Del Mastro L, Viglietti G, Pond\u00e9 NF, Solinas C, de Azambuja E (2017) Ovarian function suppression in premenopausal women with early-stage breast cancer. Curr Treat Options Oncol 18(1):4","journal-title":"Curr Treat Options Oncol"},{"issue":"14","key":"6368_CR7","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1200\/JCO.2015.64.8675","volume":"34","author":"K Ribi","year":"2016","unstructured":"Ribi K, Luo W, Bernhard J, Francis PA, Burstein HJ, Ciruelos E, Bellet M, Pavesi L, Lluch A, Visini M et al (2016) Adjuvant tamoxifen plus ovarian function suppression versus tamoxifen alone in premenopausal women with early breast cancer: patient-reported outcomes in the suppression of ovarian function trial. J Clin Oncol 34(14):1601\u20131610","journal-title":"J Clin Oncol"},{"issue":"5","key":"6368_CR8","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.fertnstert.2019.09.037","volume":"112","author":"MT Sauerbrun-Cutler","year":"2019","unstructured":"Sauerbrun-Cutler MT, Alvero R (2019) Short- and long-term impact of gonadotropin-releasing hormone analogue treatment on bone loss and fracture. Fertil Steril 112(5):799\u2013803","journal-title":"Fertil Steril"},{"issue":"2","key":"6368_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.jbi.2012.10.006","volume":"46","author":"JS Obeid","year":"2013","unstructured":"Obeid JS, McGraw CA, Minor BL, Conde JG, Pawluk R, Lin M, Wang J, Banks SR, Hemphill SA, Taylor R et al (2013) Procurement of shared data instruments for Research Electronic Data Capture (REDCap). J Biomed Inform 46(2):259\u2013265","journal-title":"J Biomed Inform"},{"issue":"2","key":"6368_CR10","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1007\/s10549-010-1132-4","volume":"126","author":"DL Hershman","year":"2011","unstructured":"Hershman DL, Shao T, Kushi LH, Buono D, Tsai WY, Fehrenbacher L, Kwan M, Gomez SL, Neugut AI (2011) Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat 126(2):529\u2013537","journal-title":"Breast Cancer Res Treat"},{"issue":"27","key":"6368_CR11","doi-asserted-by":"publisher","first-page":"3113","DOI":"10.1200\/JCO.2016.72.0946","volume":"35","author":"P Saha","year":"2017","unstructured":"Saha P, Regan MM, Pagani O, Francis PA, Walley BA, Ribi K, Bernhard J, Luo W, G\u00f3mez HL, Burstein HJ et al (2017) Treatment efficacy, adherence, and quality of life among women younger than 35 years in the international breast cancer study group TEXT and SOFT adjuvant endocrine therapy trials. J Clin Oncol 35(27):3113\u20133122","journal-title":"J Clin Oncol"},{"issue":"2","key":"6368_CR12","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1056\/NEJMoa1804710","volume":"379","author":"JA Sparano","year":"2018","unstructured":"Sparano JA, Gray RJ, Makower DF, Pritchard KI, Albain KS, Hayes DF, Geyer CE, Dees EC, Goetz MP, Olson JA et al (2018) Adjuvant chemotherapy guided by a 21-gene expression assay in breast cancer. N Engl J Med 379(2):111\u2013121","journal-title":"N Engl J Med"},{"issue":"6","key":"6368_CR13","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/JCO.20.03007","volume":"39","author":"JA Sparano","year":"2021","unstructured":"Sparano JA, Crager MR, Tang G, Gray RJ, Stemmer SM, Shak S (2021) Development and validation of a tool integrating the 21-gene recurrence score and clinical-pathological features to individualize prognosis and prediction of chemotherapy benefit in early breast cancer. J Clin Oncol 39(6):557\u2013564","journal-title":"J Clin Oncol"},{"issue":"2","key":"6368_CR14","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1056\/NEJMoa1404037","volume":"371","author":"O Pagani","year":"2014","unstructured":"Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, L\u00e1ng I, Gomez HL, Tondini C, Burstein HJ, Perez EA et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371(2):107\u2013118","journal-title":"N Engl J Med"},{"issue":"10","key":"6368_CR15","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1111\/imj.13169","volume":"46","author":"AH Hsieh","year":"2016","unstructured":"Hsieh AH, Kichenadasse G, Vatandoust S, Roy A, Sukumaran S, Karapetis CS, Martin H, Chong LC, Koczwara B (2016) Goserelin toxicities and preferences for ovarian suppression method in pre-menopausal women with breast cancer. Intern Med J 46(10):1153\u20131159","journal-title":"Intern Med J"},{"issue":"11","key":"6368_CR16","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1007\/s40261-017-0571-7","volume":"37","author":"G Ferrandina","year":"2017","unstructured":"Ferrandina G, Amadio G, Marcellusi A, Azzolini E, Puggina A, Pastorino R, Ricciardi W, Scambia G (2017) Bilateral salpingo-oophorectomy versus GnRH analogue in the adjuvant treatment of premenopausal breast cancer patients: cost-effectiveness evaluation of breast cancer outcome, ovarian cancer prevention and treatment. Clin Drug Investig 37(11):1093\u20131102","journal-title":"Clin Drug Investig"},{"issue":"5","key":"6368_CR17","doi-asserted-by":"publisher","first-page":"e939","DOI":"10.1016\/j.clbc.2018.04.005","volume":"18","author":"DC Kendzierski","year":"2018","unstructured":"Kendzierski DC, Schneider BP, Kiel PJ (2018) Efficacy of different leuprolide administration schedules in premenopausal breast cancer: a retrospective review. Clin Breast Cancer 18(5):e939\u2013e942","journal-title":"Clin Breast Cancer"},{"issue":"6","key":"6368_CR18","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1007\/s002800050924","volume":"43","author":"F Boccardo","year":"1999","unstructured":"Boccardo F, Rubagotti A, Amoroso D, Agostara B, Amadori D, Gallo L, Iacobelli S, Massidda B, Mesiti M, Pacini P et al (1999) Endocrinological and clinical evaluation of two depot formulations of leuprolide acetate in pre- and perimenopausal breast cancer patients. Cancer Chemother Pharmacol 43(6):461\u2013466","journal-title":"Cancer Chemother Pharmacol"},{"issue":"14","key":"6368_CR19","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1200\/JCO.2015.61.2259","volume":"34","author":"M Bellet","year":"2016","unstructured":"Bellet M, Gray KP, Francis PA, L\u00e1ng I, Ciruelos E, Lluch A, Climent MA, Catal\u00e1n G, Avella A, Bohn U et al (2016) Twelve-month estrogen levels in premenopausal women with hormone receptor-positive breast cancer receiving adjuvant triptorelin plus exemestane or tamoxifen in the suppression of ovarian function trial (SOFT): the SOFT-EST substudy. J Clin Oncol 34(14):1584\u20131593","journal-title":"J Clin Oncol"},{"issue":"3","key":"6368_CR20","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1200\/JCO.2005.04.5393","volume":"25","author":"J Bernhard","year":"2007","unstructured":"Bernhard J, Zahrieh D, Castiglione-Gertsch M, H\u00fcrny C, Gelber RD, Forbes JF, Murray E, Collins J, Aebi S, Th\u00fcrlimann B et al (2007) Adjuvant chemotherapy followed by goserelin compared with either modality alone: the impact on amenorrhea, hot flashes, and quality of life in premenopausal patients\u2013the International Breast Cancer Study Group Trial VIII. J Clin Oncol 25(3):263\u2013270","journal-title":"J Clin Oncol"},{"key":"6368_CR21","doi-asserted-by":"crossref","unstructured":"Llarena NC, Estevez SL, Tucker SL, Jeruss JS (2015) Impact of fertility concerns on tamoxifen initiation and persistence. J Natl Cancer Inst 107(10)","DOI":"10.1093\/jnci\/djv202"},{"issue":"20","key":"6368_CR22","doi-asserted-by":"publisher","first-page":"2262","DOI":"10.1200\/JCO.2014.59.3673","volume":"33","author":"W He","year":"2015","unstructured":"He W, Fang F, Varnum C, Eriksson M, Hall P, Czene K (2015) Predictors of discontinuation of adjuvant hormone therapy in patients with breast cancer. J Clin Oncol 33(20):2262\u20132269","journal-title":"J Clin Oncol"},{"issue":"1","key":"6368_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s10549-020-05920-y","volume":"185","author":"M Yusufov","year":"2021","unstructured":"Yusufov M, Nathan M, Wiley A, Russell J, Partridge A, Joffe H (2021) Predictors of increased risk for early treatment non-adherence to oral anti-estrogen therapies in early-stage breast cancer patients. Breast Cancer Res Treat 185(1):53\u201362","journal-title":"Breast Cancer Res Treat"},{"issue":"4","key":"6368_CR24","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1002\/pon.5289","volume":"29","author":"JC Spencer","year":"2020","unstructured":"Spencer JC, Reeve BB, Troester MA, Wheeler SB (2020) Factors associated with endocrine therapy non-adherence in breast cancer survivors. Psychooncology 29(4):647\u2013654","journal-title":"Psychooncology"},{"issue":"1","key":"6368_CR25","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1007\/s11764-019-00800-x","volume":"14","author":"SL Bober","year":"2020","unstructured":"Bober SL, Fine E, Recklitis CJ (2020) Sexual health and rehabilitation after ovarian suppression treatment (SHARE-OS): a clinical intervention for young breast cancer survivors. J Cancer Surviv 14(1):26\u201330","journal-title":"J Cancer Surviv"},{"key":"6368_CR26","doi-asserted-by":"crossref","unstructured":"Vaughn J, Ammerman C, Stein J (2020) ASCO abstract: delay discounting as a predictor of adjuvant endocrine therapy adherence among breast cancer survivors. In., vol. 38:15. J Clin Oncol","DOI":"10.1200\/JCO.2020.38.15_suppl.e24172"},{"issue":"8","key":"6368_CR27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1080\/02841860050215945","volume":"39","author":"M Nystedt","year":"2000","unstructured":"Nystedt M, Berglund G, Bolund C, Brandberg Y, Fornander T, Rutqvist LE (2000) Randomized trial of adjuvant tamoxifen and\/or goserelin in premenopausal breast cancer\u2013self-rated physiological effects and symptoms. Acta Oncol 39(8):959\u2013968","journal-title":"Acta Oncol"}],"container-title":["Breast Cancer Research and Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10549-021-06368-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10549-021-06368-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,31]],"date-time":"2021-10-31T17:05:44Z","timestamp":1635699944000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10549-021-06368-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,8]]},"references-count":27,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,11]]}},"alternative-id":["6368"],"URL":"https:\/\/doi.org\/10.1007\/s10549-021-06368-4","relation":{},"ISSN":["0167-6806","1573-7217"],"issn-type":[{"value":"0167-6806","type":"print"},{"value":"1573-7217","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,8]]},"assertion":[{"value":"18 May 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflict of interest to disclose.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}